Multiple Sclerosis

dc.contributor.authorYamout, Bassem I.
dc.contributor.authorAlroughani, Raed A.
dc.contributor.departmentNeurology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:07:33Z
dc.date.available2025-01-24T12:07:33Z
dc.date.issued2018
dc.description.abstractMultiple sclerosis (MS) is a chronic central nervous system inflammatory disease of autoimmune etiology, mediated by activated T cells with evolving evidence of a significant contribution from B cells and cells of the innate immune system. The disease is thought to be due to a complex interaction between different genetic and environmental factors. The prevalence of MS is rising all over the world, due on one hand to earlier diagnosis and prolonged survival, and on the other to a true increase in incidence of the disease. The diagnosis of MS remains clinical despite recent advances in diagnostics and relies on demonstrating dissemination in space and time while excluding alternative diagnoses. The Mc Donald diagnostic criteria, with their recent 2017 revision, are currently widely accepted in the MS community. Although no cure is yet available, many disease-modifying therapies (DMTs) have shown different levels of efficacy in preventing relapses, accumulation of lesions on magnetic resonance imaging (MRI), and disability progression. Current treatment strategies include gradual escalation based on clinical and radiological criteria that determine treatment response, or initial induction with high efficacy DMTs especially in patients with an early aggressive course. © 2018 by Thieme Medical Publishers, Inc.
dc.identifier.doihttps://doi.org/10.1055/s-0038-1649502
dc.identifier.eid2-s2.0-85047512796
dc.identifier.pmid29791948
dc.identifier.urihttp://hdl.handle.net/10938/31558
dc.language.isoen
dc.publisherThieme Medical Publishers, Inc.
dc.relation.ispartofSeminars in Neurology
dc.sourceScopus
dc.subjectDiagnosis
dc.subjectMultiple sclerosis
dc.subjectReview
dc.subjectTreatment guidelines
dc.subjectAnti-inflammatory agents
dc.subjectDisease management
dc.subjectHumans
dc.subjectMagnetic resonance imaging
dc.subjectAlemtuzumab
dc.subjectFingolimod
dc.subjectFumaric acid dimethyl ester
dc.subjectGlatiramer
dc.subjectInterferon
dc.subjectNatalizumab
dc.subjectOcrelizumab
dc.subjectTeriflunomide
dc.subjectAntiinflammatory agent
dc.subjectArticle
dc.subjectAutoimmune disease
dc.subjectB lymphocyte
dc.subjectClinical feature
dc.subjectDisability
dc.subjectDisease course
dc.subjectEnvironmental factor
dc.subjectHuman
dc.subjectImmunopathogenesis
dc.subjectIncidence
dc.subjectInnate immunity
dc.subjectNonhuman
dc.subjectNuclear magnetic resonance imaging
dc.subjectPhase 3 clinical trial (topic)
dc.subjectPhenotype
dc.subjectPriority journal
dc.subjectRandomized controlled trial (topic)
dc.subjectRelapse
dc.subjectSurvival
dc.subjectT lymphocyte activation
dc.subjectTreatment response
dc.subjectGenetics
dc.titleMultiple Sclerosis
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-8245.pdf
Size:
1.97 MB
Format:
Adobe Portable Document Format

Collections